The 7-OH Lesson: When Product Innovation Creates Regulatory Risk
It started with a botanical. Then manufacturers concentrated one of its trace compounds, creating products that could expose consumers to far more 7-OH than natural kratom leaf. What looked like product innovation became a safety concern, then a regulatory problem, and now a potential threat to businesses built around it.
The 7-OH story shows how quickly changing what is inside a product can change the future of the product itself.
← Back to InsightsWhat changed?
Kratom leaf naturally contains many compounds. Its main alkaloid is mitragynine. 7-hydroxymitragynine, or 7-OH, is also present, but naturally occurs only in very small amounts.
Manufacturing changed that relationship. Products began appearing with 7-OH at levels far beyond what would normally be found in kratom leaf. The ingredient still had a connection to the botanical, but the finished product no longer represented the same exposure.
Kratom leaf → processing and manufacturing → concentrated 7-OH → different exposure → increased safety concern → regulatory scrutiny → commercial consequences.
Why did concentration change the problem?
The important issue is not simply that 7-OH comes from kratom. It is how much consumers are exposed to in the finished product.
Natural kratom leaf contains 7-OH at trace levels. Concentrated products can deliver substantially more. That matters because 7-OH has strong opioid activity, and FDA has raised concerns about addiction, withdrawal and other serious effects associated with concentrated products.
So saying “it occurs naturally in kratom” does not settle the safety or regulatory question when manufacturing has substantially changed the exposure.
Then regulators started acting
The warning signs are no longer theoretical. FDA issued warning letters in 2025 to companies marketing concentrated 7-OH products. In December 2025, FDA and the U.S. Marshals Service seized about 73,000 units of concentrated 7-OH products valued at approximately $1 million. A 2026 recall also involved tablets containing more 7-OH than the amount declared on the label.
On July 1, 2026, DEA announced the start of the process to temporarily place 7-OH above a specified threshold, together with three related substances, into Schedule I under the Controlled Substances Act.
This does not mean all natural kratom leaf has been federally placed into Schedule I. DEA's announced action distinguishes elevated concentrations of 7-OH and related substances from botanical kratom containing naturally occurring 7-OH below the proposed threshold.
The process is still developing. On August 26, 2026, HHS extended the public-comment period concerning where the 7-OH threshold should be set and how that threshold should be measured.
For manufacturers, that distinction is significant: concentration is no longer merely a formulation specification. It can affect the regulatory future of the product.
What does this mean for companies?
A company can invest in an ingredient, formulate products, manufacture inventory, develop packaging and build distribution before discovering that regulators view the finished product very differently from the botanical it came from.
By then, the problem is no longer confined to science. It can affect inventory, retailers, marketing, distribution, legal exposure and the money already invested in the product.
The fact that something comes from a botanical does not protect the finished product when manufacturing changes what consumers are actually exposed to.
Product innovation can change the science that originally made an ingredient attractive. If that change is not recognized early, the commercial consequences may arrive after substantial money has already been committed.
The risk can begin before regulators arrive
Regulatory action can appear sudden. The conditions behind it often develop much earlier.
An ingredient becomes more concentrated. A supplier offers a stronger version. Processing changes. The formulation delivers a substantially different exposure. Marketing then builds around the stronger effect.
At some point, the assumptions attached to the original botanical may no longer describe the product being sold.
That is why the expensive question is often not “What do we do now that regulators are interested?” but “Could we have identified this risk before we built the product around it?”
7-OH and mitragynine should not be treated as pharmacologically interchangeable simply because both are associated with kratom. Experimental evidence shows stronger μ-opioid receptor activity and different abuse-related effects for 7-OH. Mitragynine can also be metabolized to 7-OH, while 7-OH can undergo further metabolism to mitragynine pseudoindoxyl. Much of the mechanistic and abuse-liability evidence remains preclinical, while FDA has also identified growing human exposure, dependence and withdrawal concerns associated with concentrated 7-OH products.
The bigger lesson goes beyond kratom
The same principle can apply whenever companies work with concentrated botanical extracts, novel ingredients, new processing methods or unusually potent formulations.
A product's risk is not determined only by the name of its starting ingredient. Processing, concentration, formulation, dose and the resulting consumer exposure can change what the finished product actually is.
When those things change, the evidence, safety assumptions, claims and regulatory position may need to be reconsidered too.
Before significant money is committed to a product, companies should know whether something about the ingredient, concentration, processing, formulation or claims has created a scientific or regulatory risk they have not recognized.
- U.S. Drug Enforcement Administration. DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety. July 1, 2026. View source
- U.S. Department of Health and Human Services. Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period. August 26, 2026. View source
- U.S. Food and Drug Administration. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. View source
- Hemby SE, et al. Abuse liability and therapeutic potential of the Mitragyna speciosa alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology. 2019. View study
- Kruegel AC, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science. 2019. View study
- U.S. Food and Drug Administration. FDA Seizes 7-OH Opioids to Protect American Consumers. December 2, 2025. View source
Could Your Product Be Carrying a Risk You Have Not Identified?
Before more money goes into formulation, manufacturing, claims or launch, find out whether the science behind your ingredient and finished product supports the decisions you are making.
Find Out Before You Invest Further